The development of newer strategies to improve outcomes for older patients with secondary acute myeloid leukemia (s-AML) is a critical unmet need. Establishing baseline metrics for evaluating newer approaches is important. METHODS: s-AML was defined as 1 or more of the following: a history of an antecedent hematologic disorder (AHD), a diagnosis of therapy-related acute myeloid leukemia (AML), and AML with karyotype abnormalities characteristic of myelodysplastic syndrome. Newly diagnosed s-AML patients aged 60 to 75 years were grouped into 5 treatment cohorts: 1) patients receiving high-or intermediate-dose cytarabinebased intensive chemotherapy (IC), 2) patients receiving a hypomethylating agent (HMA) or HMA combinations, 3) patients receiving low-dose cytarabine (LDAC) combinations, 4) patients receiving CPX-351, and 5) patients receiving investigational (INV) agents. Nine hundred thirty-one patients met the age and s-AML criteria. RESULTS: Complete remission rates were statistically lower in the HMA group (36%) versus the IC (46%), CPX-351 (45%), and LDAC groups (43%). Patients receiving less intensive regimens (the HMA and LDAC groups combined) had superior overall survival (OS) in comparison with patients receiving IC-based regimens (median 6.9 vs 5.4 months; P 5 .048). Only 4.3% of the IC patients proceeded to transplantation, whereas 10.3% of the patients on lower intensity regimens did (P 5 .001). There was no difference in median survival between patients treated with CPX-351 and patients treated with conventional lower intensity approaches (P 5 .75). Age > 70 years, an adverse karyotype, and a prior AHD were associated with decreased OS in a multivariate analysis. CONCLUSIONS: Lower intensity approaches are associated with lower early mortality rates and improved OS in comparison with intensive regimens. OS is poor with currently available therapies with a median OS of 6 months (5.4-7.6 months across regimens). Unsatisfactory outcomes with other INV agents underscore the need for more effective therapies.
INTRODUCTION
Acute myeloid leukemia (AML) has been broadly categorized as de novo AML and secondary acute myeloid leukemia (s-AML) on the basis of the absence or presence of a preleukemic hematologic disorder or therapy-related malignancies, respectively.
1 s-AML is a heterogeneous and poorly defined category of disease entities that includes 1) AML secondary to prior myelodysplastic syndrome (MDS), myeloproliferative neoplasm (MPN), and aplastic anemia, among others (s-AML), and 2) the development of AML secondary to a proven leukemogenic chemotherapeutic exposure (therapy-related acute myeloid leukemia [t-AML]). 2 It has long been recognized that cytogenetic and molecular characteristics are major players in the disease prognosis, and this has resulted in a gradual evolution of AML classification schemes from a morphology-based French-American-British system to a more prognostically informative classification incorporating cytogenetic and molecular abnormalities. [3] [4] [5] In its 2008 revision, the World Health Organization refined its classification scheme by incorporating a new subcategory of AML defined as AML with myelodysplasia-related changes; it includes AML from prior MDS or MDS/MPN, AML with a specific MDS-related cytogenetic abnormality, and AML with morphological evidence of multilineage dysplasia. 5 In the most recent 2016 update, AML with myelodysplasia-related changes and therapy-related myeloid neoplasms have been retained as distinct categories.
Age, cytogenetics, and antecedent myeloid malignancies are well established independent prognostic risk factors in defining AML outcomes. 7, 8 Older patients (>60 years) experience significantly lower remission rates and disease-free survival in comparison with their younger counterparts, 9 with the median time from treatment to death on conventional induction therapy estimated to be 5 to 10 months. 9, 10 Further refinements in prognostication have identified a relatively favorable prognostic group among these patients characterized by a younger age (55-65 years), de novo AML, a favorable/intermediate cytogenetic profile, and a lack of multidrug resistance expression 11 ; for this group, a cytarabine-based induction approach may be prioritized to improve survival. However, this likely excludes an older group of patients (>65 years) who derive minimal overall survival (OS) benefit from conventional induction chemotherapy. 12, 13 Palliation is often considered the only reasonable option for patients at an advanced age (>80 years) or for elderly patients with a performance status of 3 to 4. 9, 14, 15 Patients aged 60 to 75 years with high-risk disease features but minimal comorbidities and a good performance status represent a subset of patients for whom there currently exists no recommended standard of care. In an effort to identify the most appropriate therapeutic strategy, we sought to review our own experience with various treatment approaches for these high-risk patients. Establishing baseline metrics with which to evaluate and develop newer investigational (INV) strategies is important.
MATERIALS AND METHODS
A retrospective chart review was performed to evaluate older patients (60-75 years old) with newly diagnosed AML who were treated at our institution from 1990 to 2015. All patients were treated and analyzed under study protocols approved by the instiutional review board and studies were conducted in accordance with the Declaration of Helsinki. The patients were grouped into 5 study cohorts according to their treatment regimen: 1) patients receiving high-or intermediate-dose cytarabine-based intensive chemotherapy (IC), 2) patients receiving a hypomethylating agent (HMA) or HMA combinations, 3) patients receiving liposomal cytarabine:daunorubicin (CPX-351), 4) patients receiving low-dose cytarabine (LDAC) combinations, and 5) patients receiving other INV agents. Induction therapy for patients in group 1 consisted of either high-dose cytarabine or a 713-based regimen. Azacytidine and decitabine therapies, alone or in combination with other INV therapies, were used for the second group (HMA patients). Patients who received nonconventional care and/or exclusively novel therapies were grouped under the INV category.
Patient Population
Inclusion required a diagnosis of newly diagnosed AML, treatment at The University of Texas MD Anderson Cancer Center, and 1 or more of the following characteristics: 1) a history of an antecedent hematologic disorder (AHD; specifically prior MDS, MPN, or aplastic anemia), 2) a diagnosis of t-AML, and 3) AML with karyotype abnormalities characteristic of MDS as defined by the World Health Organization. 6 Patients with a very poor performance status (3) were excluded. AML was defined as the presence of at least 20% myeloid blasts in the bone marrow. Patients' karyotypes were divided as follows: an adverse karyotype (complex: >2 chromosomal abnormalities or a Del 5/5q, Del 7/7q, 11q, or 3q abnormality), a diploid karyotype, and an intermediate karyotype (a karyotype other than an adverse or diploid one). We accorded a separate category for the diploid karyotype to establish a baseline comparison against which other karyotypes could be compared. We did not include the mutation status in our study analysis because we did not have molecular information for a large proportion of our patients, most of whom were treated in the pre-mutation profiling era of AML. 16 Other study variables included in the analysis were the t-AML status (chemotherapy for prior malignancies) and therapy for prior AHD.
Study Endpoints
Study endpoints included the complete response (CR)/ complete response with low platelets (CRp) rate according to the international working group criteria, 17 the OS, and the 8-week mortality rate. OS was calculated from the time of the AML diagnosis to the date of death and was censored at the time of the last follow-up date if the patient was alive.
Statistical Analysis
Descriptive statistics were presented as medians and ranges for continuous data and as numbers and percentages for dichotomous/categorical data. Chi-square and Mann-Whitney U tests were used to assess patient characteristics for the categorical and continuous data, respectively. Survival curves with Kaplan-Meier estimates were used to compare OS between groups, and the survival curves were compared with log-rank tests. Univariate and multivariate analyses were performed to examine the relations between disease characteristics and disease outcomes (CR and OS). Only patients with a known karyotype were analyzed in the multivariate analysis. Logistic 148 (37) 35 (16) 5 (25) 40 (22) 18 (17) <.001
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RESULTS
We evaluated a total of 931 patients with newly diagnosed AML who met the criteria for age and disease characteristics. The median age was 68 years (range, 60-75 years). Karyotype information was available for 89% of the patients. Among the patients for whom we had karyotype information, 17% had a diploid karyotype, 58% had an adverse-risk profile, and 14% had an intermediate-risk profile (excluding a diploid karyotype). All patients had a performance status 2. Molecular information was not available for a majority of the patients and hence was not included in the study analysis. Prognostically relevant intergroup differences were observed with respect to age (there was a larger percentage of younger patients in group 1; Table 1 ). Intergroup differences were also observed in other parameters such as lactate dehydrogenase levels, creatinine levels, bone marrow blasts, and a history of AHD. According to further analysis of an AML population with highrisk disease characteristics (ie, a white blood cell count 50 K/lL, a creatinine level 1.3 mg/dL, a performance status of 2, and a history of AHD), the CPX-351 arm had a much higher proportion of patients with AHD in comparison with all other categories except for the INV group (Table 2 ). In addition, only 1% of the AML patients treated with HMA-based therapies (2 of 221) had a white blood cell count > 50 K/lL; this was significantly lower than the rate in the other treatment groups. Patients within the INV group were significantly older than patients in the other treatment category of patients (58% of the patients were older than 70 years; Table 2 ). The induction therapies for each of the study groups are illustrated in Supporting Figures 1 to 4 (see online supporting information). Treatment regimens for which there were fewer than 10 study patients were placed in the other category. The overall CR/CRp rate for the entire group was 39.5%. Table 3 summarizes a univariate analysis of CR/ CRp by patient and disease characteristics. In the univariate analysis, prior treatment for AHD, age, cytogenetics, and type of treatment had an impact on the response rates achieved. Patients who had prior treatment for AHD had inferior response rates (24.5% vs 45%; P < .001). In addition, adverse and intermediate-risk (nondiploid) karyotypes, in comparison with diploid karyotypes, predicted inferior responses to therapy (39% vs 52% [P 5 .001] and 37% vs 52% [P 5 .002], respectively). Complete remission rates were lower in the HMA (36%) and INV groups (16%) in comparison with the IC group (46%; P 5 .03 and P 5 .001, respectively). In the multivariate analyses, 5 factors correlated with rates of response to induction therapy. Treatment with epigenetic (HMAbased) and INV agents, the presence of intermediate (excluding diploid) and adverse karyotypes, and a history of prior treatment for AHD negatively affected response rates ( Table 4 ). The 8-week mortality rate was 20% for the entire group, 23% for the IC group, 12% for the HMA group, 10% for the CPX-351 group, 19% for the LDAC group, and 27% for the INV/other group.
The median OS for the entire group was 6 months. OS by each treatment cohort is shown in Figure 1 . There was a significant difference in OS between the 5 treatment groups (P 5 .002). No statistically significant difference in median survival was identified when individual lower intensity treatment groups were compared against one another. However, despite a lower CR rate, there was a trend toward improved median survival among patients receiving HMA-based therapy versus standard intensivecare therapies (6.7 vs 5.4 months; P 5 .058) and INV agents (6.7 vs 4.6 months; P 5 .06). Altogether, patients who received less intensive (HMA-and LDAC-based) regimens had superior median OS in comparison with those receiving IC-based regimens (6.9 vs 5.4 months; P 5 .048; Fig. 2 ). There was no difference in median survival between patients treated with CPX-351 and patients treated with conventional lower intensity approaches (HMA and LDAC; P 5 .75). Notably, an OS analysis performed for patients with t-AML by therapy regimen (ie, IC regimen vs epigenetic and LDAC regimens) did not demonstrate a statistically significant difference in OS (6 vs 5.6 months; P 5 .92; data not shown).
Patients who received a transplant (7.1%) had superior outcomes in terms of median survival (OS) in comparison with patients who did not proceed to transplantation after chemotherapy (16.2 vs 5.5 mo, respectively; P < .001; Fig. 3A ). Forty percent of the transplant patients belonged to the age cohort of 60 to 65 years, whereas 18.5% of the patients who did not receive a transplant belonged to that cohort (P < .001). Superior survival outcomes with transplantation were observed across the groups, regardless of treatment with IC (OS, 20.8 mo for the transplant arm vs 5 mo for the nontransplant arm; P < .001; Fig. 3B ) or lower intensity approaches (OS, 16.2 mo for the transplant arm vs 6.2 mo for the nontransplant arm; P < .001; Fig. 3C ). Patients who proceeded to transplantation constituted only 4.3% of the IC group (median age, 64 years), whereas 10.3% of the patients who received lower intensity regimens were able to proceed to transplantation (median age, 66 y; P 5 .001). To assess the possible reasons for this paradoxical disparity in proportions, we performed a survival analysis comparing survival among lower intensity complete responders and IC complete responders. For this analysis, survival was calculated from the time of CR to death or was censored at the time of transplantation or last followup if neither death nor transplantation occurred (Fig.  3D) . The median survival time for complete responders was 12.8 months with low-intensity approaches and 10.3 months with high-intensity approaches (P 5 .41). On closer inspection, we found that the intersection of survival curves early after CR created a lack of statistically significant survival difference.
According to the univariate analyses, the type of treatment approach, age, cytogenetics, and prior treatment for AHD were associated with differences in OS (Table 3 ). In the multivariate Cox regression analysis, an age > 70 years, an adverse karyotype, and prior treatment for AHD were associated with significantly decreased OS (Table 4) .
DISCUSSION
Unlike the younger AML population, older AML patients have witnessed little improvement in their prognosis over the past few decades. 18 The improvement in outcomes for the younger AML population is partly related to more effective postremission therapies. 19 In contrast to the younger AML patients, postremission therapy has been shown to be of limited value for older patients. 20 Although low-risk older AML patients may achieve remission rates up to 50% with the standard 713-based approach, the risk of relapse is as high as 85% at 3 years. 21 These response rates drop to less than 30% for patients with high-risk cytogenetics. 8, 22 High-dose cytarabinebased therapies may result in an improved response duration in patients who respond, but this comes at the cost of increased early treatment-related mortality. This is of major consequence for older AML patients, the majority of whom do not tolerate standard induction doses. Randomized controlled trials comparing standard induction and less intensive chemotherapies in older AML patients are scarce, and there is currently no recommended standard of care for the management of this subset of patients, with the National Comprehensive Care Network and European LeukemiaNet divided in opinion on the optimal mode of therapeutic strategy. One of the major challenges in conducting comparison trials of intensive and nonintensive therapies in older AML patients is concern over issues related to tolerability, comorbidity, and performance status, among others. In this context, conducting trials in AML patients with high-risk prognostic features calls for further genomic annotation to define who may benefit from cytarabine-based therapy. The most recently updated European LeukemiaNet guidelines recommend a standard induction cytarabine-anthracycline-based regimen for patients aged 60 to 74 years with a good performance status and favorable cytogenetics. They suggest an INV treatment approach for patients with adverse-risk cytogenetics because they recognize the significant impact that cytogenetics have on the response to standard induction therapy. 23, 24 National Comprehensive Care Network guidelines recommend participation in a clinical trial, treatment with standard therapy, or treatment with lower intensity approaches, including HMAs (azacytidine and decitabine) and LDAC. 25 Azacytidine and decitabine are the 2 most commonly used low-intensity therapies along with LDAC in the management of AML. It is important to note that responses in patients receiving HMAs may not be evident until after a few cycles of therapy. For example, in older patients (65 years) with newly diagnosed AML treated with decitabine, the median time to a response for patients achieving a CR/CRp was 4.3 months. 26 In our study, only 36% of the patients on HMA-based regimens showed a CR; this rate was far lower than the CR rate achieved with IC (45%). In fact, the multivariate analysis in our study showed that the use of HMAs was a predictor of a decreased CR rate. However, we observed that this was not reflected in the OS rates, as shown by the trend toward superior median OS for patients who received HMA-based therapy versus those who received IC. 27 In this respect, the OS of patients receiving HMA therapy may not be predicted by the type of response as much as by the evidence of any degree of improvement (CR, partial response, or hematologic improvement), including stable disease. 28 Furthermore, retrospective data have suggested the possible superiority of HMAs over traditional cytotoxic agents in patients with adverse-risk cytogenetics. 29 Achieving complete remission may be of lesser importance for an older AML patient whose primary goal of therapy is to improve survival while maintaining his or quality of life rather than achieve a cure by proceeding to transplantation. 30, 31 That said, reduced-intensity nonmyeloablative chemotherapy/transplantation may still be an option, if applicable, for select patients. Interestingly, we noted that a lower percentage of AML patients in the IC arm were able to proceed to transplantation in comparison with patients who received low-intensity therapy (4.3% vs 10.3%, respectively; P < .001) despite higher CR rates in the IC arm. Although there was no statistically significant survival difference between the 2 groups, the separation of the survival curves later in the time course suggests that complete responders on lower intensity approaches seem to fare better than complete responders on high-dose IC approaches (Fig. 3D) . One might surmise that a lower proportion of patients proceeded to transplantation in the IC arm likely in part because of the higher rates of morbidity (which are not systematically captured) and mortality in this group, which precluded the option of transplantation. Also, patients on the lower intensity approaches (eg, clofarabine/cladribine plus LDAC or HMA) are typically able to continue receiving further cycles; thus, their response is maintained while they await transplantation, and relapse-related mortality is averted. Nevertheless, there may have been other factors involved, including the availability of a suitable donor, the patient/physician choice of therapy, and fitness for transplantation. A study assessing the feasibility of reduced-intensity allotransplantation during first CR in older AML patients demonstrated improved event-free survival and OS. However, the median age of the stem cell transplantation (SCT) patients was 57 years, with only 6 patients above the age of 60 years, and only 2 patients had an adverse karyotype. 32 A prospective study in older patients (>60 years) is required to address the feasibility of nonmyeloablative transplantation in higher risk settings. After limited success with the addition of various agents to the cytarabine:daunorubicin backbone, attempts were made to optimize efficacy by locking both agents in a fixed ratiometric dosing within a liposomal drug carrier. 33 Preclinical leukemic models showed markedly improved efficacy with CPX-351 against leukemic blasts.
33,34 A multicenter, randomized phase 2 trial data analysis reported an improved response rate (57.6% vs 31.6%; P 5 .06) and increased OS (12.1 vs 6.1 months; hazard ratio, 0.46; P 5 .01) in older s-AML patients assigned to CPX-351 versus the conventional 713 regimen. 35 Importantly, responses were not affected even if patients had received HMAs for prior MDS. The superior efficacy was later confirmed in a phase 3 trial comparing CPX-351 with standard 713 induction chemotherapy (OS, 9.56 vs 5.95 months [P 5 .005]; CR plus complete response with incomplete blood count recovery, 47.7% vs 33.3% [P 5 .016]). 36 Our data on outcomes for patients who received CPX-351 compared less favorably, in terms of response rates and median survival, with data from both of these trials. 35, 36 The reason for the lower median survival observed in our CPX-351 study group may be related to differences in the dosing of CPX-351 and to a higher percentage of patients with poor-risk disease (45% with an adverse karyotype and 75% older than 65 years).
31,37 Furthermore, we did not observe a statistical difference in median OS between the CPX-351 and IC groups. This may again be due to the lower median survival, in comparison with historical data, for the CPX-351 group secondary to factors mentioned previously and due to the nature of the comparator IC arm, which included regimens such as idarubicin and high-dose cytarabine and fludarabine, idarubicin, and cytarabine (with both regimens containing higher dose cytarabine), among others. Finally, patients who received other conventional lowintensity treatments (HMA and LDAC therapies) had similar OS when they were compared with patients who received CPX-351 (P 5 .75). This is especially important to note in the context of CPX-351 as a potential first-line option for high-risk AML patients.
Cytarabine may be administered at a reduced dose (LDAC) to patients who may not tolerate standarddosing induction chemotherapy. LDAC is an alternative for older, infirm AML patients who would otherwise not tolerate standard induction. 38 However, LDAC alone is not considered curative and is not favored among physicians because of its minimal efficacy. CR rates can vary from 0% to more than 30% according to whether the cytogenetics are adverse or favorable, respectively. 13, [39] [40] [41] Efforts to improve outcomes have resulted in a bevy of clinical trials of novel agents in combination with LDAC. Purine nucleoside analogs, in particular, have proven to be effective in improving response rates and median survival when they are used in combination with LDAC. 42, 43 A propensity score-matched comparison of patients given clofarabine and LDAC instead of standard induction chemotherapy among older AML patients (>60 years) found the former to be noninferior with no differences in response rates or OS. As expected, the lower intensity therapy patient cohort also experienced few toxicities. 44 A number of other novel therapeutics have been entered into trials either as single agents or in combination with other low-intensity agents. Trials using these agents in combination regimens with LDAC have shown improvements in response rates and OS in comparison with LDAC alone. Among them, volasertib (a Polo-like kinase 1 inhibitor), 45 vosaroxin (a quinolone derivative that is a topoisomerase II inhibitor), 46 guadecitabine (a dinucleotide of decitabine and deoxyguanosine), 47 gemtuzumab ozogamicin, 48 and venetoclax 49 are notable. Our data on the LDAC group compare favorably with historical data on LDAC alone, and this is likely due to the fact that almost all our patients belonging to the LDAC group were on combination regimens (Supporting Fig. 2 [see online supporting information]). Of consequence is the fact that this group did not perform inferiorly to other groups in terms of either response rates or median survival, despite the majority having adverse cytogenetics (a major factor determining the response to LDAC). This points to the potential effects of combining agents (eg, clofarabine or cladribine) with LDAC to circumvent the problem of poor responsiveness to LDAC.
Most prior studies assigned low-intensity therapy approaches to patients considered unfit for IC. One of the important strengths of our study is that patients in each group were fairly well balanced in prognostically relevant disease characteristics and had minimal comorbidities and a reasonable performance status. This allowed us to comment on and make comparisons of various treatment approaches in these high-risk patients considered to be in the zone of therapeutic uncertainty. Our study may be criticized on several grounds. Our methods involved a retrospective study design that suffers from its inherent limitations, including a potential for treatment-selection biases. We did not have data and hence were not able to include the molecular status, an emerging prognostic factor for AML outcomes. Recent studies have shown that specific molecular mutation patterns have an impact on response durations and survival outcomes.
50,51 Molecular characterization will facilitate further prognostic risk stratification of this high-risk AML population. Efforts are underway to prospectively molecularly characterize all new AML patients at our institution. The CPX-351 cohort consisted of a small group of patients, and this may have contributed to the statistical insignificance despite high CR rates and a median survival of 7.6 months. However, results from this study should encourage future prospective studies comparing CPX-351 with other lower intensity approaches. Patient assignment in 2 of the 5 groups was based on the intensity of the cytarabine backbone, regardless of what the other combination agents involved were (ie, either standard induction or LDACbased). The resulting within-group heterogeneity caused by the pooling of intervention regimens of varying efficacy would undermine external validity comparisons. That said, the primary intention of this study was to examine relations between disease characteristics and outcomes and to assess response rates and OS with different types of therapies.
Acknowledging these limitations, we can make a few generalizations. The outcomes of older patients with newly diagnosed high-risk AML are poor and reflect their advanced age and poor-risk karyotype. Patients on standard-induction and high-dose cytarabine regimens have marginally higher CR rates but also experience higher 8-week treatment mortality. In comparison, patients on lower intensity approaches involving HMAand LDAC-based regimens experience lower early mortality with a trend toward improved OS. No single treatment group is predictive of improved survival, but lower intensity regimens promise longer survival and lower early mortality in comparison with high-intensity regimens. Our study data on the INV group are disappointing in light of the need for new treatments, but we refrain from commenting further because of the many different novel agent combinations used in this group. Also, patients in the INV group were older and had other high-risk features. The less than optimal outcomes in this group are likely related in part to selection biases associated with the retrospective study analysis.
In conclusion, the results of our study reiterate the fact that standard induction or high-intensity regimens would not be the ideal option for older AML patients who harbor poor-risk disease characteristics. With improvements in supportive care and tools predicting treatmentrelated mortality with reasonable accuracy, the decision of which therapy to provide to this subset of patients is a
Original Article challenge that is still open to debate and requires intensive study. 20 Results from our study should help us to reflect on the paradigm shift favoring lower intensity combination approaches even for patients who are expected to tolerate high-intensity chemotherapy. As discussed previously, patients with high-risk disease characteristics are typically resistant to conventional-care high-intensity approaches and are most appropriate for INV/low-intensity combination therapies. The rational use of newer agents in novel combinations with low-intensity cytarabine, epigenetic therapies, and liposomal agents such as CPX-351 may be the best step for improving outcomes for these patients. The choice of an appropriate therapy must be made after due consideration of the applicability of reduced-intensity allotransplantation to a few select groups of patients. 52 Unfortunately, an unfavorable cytogenetic risk status predicts an increased rate of relapse after nonmyeloablative SCT. 53 It remains to be seen whether the deleterious effects of an unfavorable cytogenetic and mutational profile can be circumvented by the incorporation of novel pre-and post-SCT regimens into future INV trials. 31, 54 
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